|
|
Article: Research on nephrosis detailed by K. Takashima and co-authors.
- Article from:
- Blood Weekly
- Article date:
- May 14, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"The renoprotective effect of cilnidipine ((+/-)-2-methoxyethyl 3-phenyl-2(E)-propenyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 132203-70-4), a L/N-type calcium channel antagonist, on puromycin aminonucleoside (PAN)-induced nephrosis was investigated in rats. In the Experiment 1, rats were given an intravenous injection of PAN (70 mg/kg)," scientists in Nagano, Japan report (see also Nephrosis).
"Cilnidipine (3 mg/kg/day) and enalapril (CAS 75847-73-3, 5 mg/kg/day) were administered orally from 6 days after treatment with PAN (day 6) to day 26, and urinary analysis was performed on days 9, 15, 20 and 27. In the Experiment 11, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Drug research organization AAIPharma Inc. acquires ...
Star-News (Wilmington, NC);
September 20, 2006 ;
700+ words
... ... Inc. has purchased a French company specializing in cancer drug research, the company said Tuesday. Cvitkovic & Associes Consultants ... stumbled earlier this decade when it sought to expand beyond drug research and establish itself as a drug manufacturer, purchasing ...
|
|